Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3359609 plus pembrolizumab versus placebo plus pembrolizumab in first-line PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
NL-OMON52820Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing GSK3359609 + pembrolizumab with Placebo + pembrolizumab (2 arms). Primary endpoints: overall survival and progression-free survival. Started Jun 2020; status: completed.
02
Drugs
feladilimabpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON52820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52820.